[Form 4] Predictive Oncology Inc. Insider Trading Activity

Rhea-AI Filing Summary

Predictive Oncology Inc. (POAI) reported a Form 4 showing that Joshua Blacher, serving as Interim CFO and an officer/director, was granted 97,000 restricted stock units (RSUs) on 09/09/2025. Each RSU represents the right to one share of common stock on vesting. The RSUs vest in full on October 31, 2025, subject to continued service through that date. Following the grant, Mr. Blacher is recorded as beneficially owning 97,000 shares directly from this award. The filing is signed 09/11/2025.

Positive

• 97,000 RSUs granted to Interim CFO indicates alignment of management and shareholder interests through equity compensation
• Clear vesting date: RSUs vest in full on October 31, 2025, providing transparent retention terms

Negative

• Potential dilution because each RSU converts to one share upon vesting, increasing outstanding shares upon settlement

Insights

Corporate Governance Expert

TL;DR: Interim CFO received time‑based RSUs that align his interests with shareholders, vesting fully by October 31, 2025.

The filing documents a standard time‑based equity grant to an officer. The grant is structured as 97,000 RSUs, each convertible to one share upon vesting, which occurs in full on a single future vesting date conditioned on continued service. This is a routine executive compensation mechanism designed to retain an officer through a specified date and to align incentives with share‑price performance at vesting. The disclosure is complete regarding amount, grant type, vesting date, and reporting signature.

Securities/Compensation Analyst

TL;DR: Material details disclosed: grant size, grant date, vesting schedule, and beneficial ownership post‑grant.

The Form 4 clearly reports a 09/09/2025 award of 97,000 RSUs to Joshua Blacher with full vesting on October 31, 2025, and beneficial ownership listed as 97,000 shares following the transaction. The instrument is non‑derivative RSUs (right to common shares) with no exercise price. The filing meets Section 16 reporting requirements by identifying the reporting person, relationship to the issuer, and signature date 09/11/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blacher Joshua

(Last) (First) (Middle)

C/O PREDICTIVE ONCOLOGY INC.

91 43RD STREET, SUITE 110

(Street)

PITTSBURGH PA 15201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Predictive Oncology Inc. [ POAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A		97,000(1)	A	$0.00	97,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on October 31, 2025, subject to continued service through the applicable vesting date.

	/s/ Josh Blacher	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.